ICP-332 clinical trials
Also written ICP-332.
How each study uses ICP-332 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ICP-332 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Beijing InnoCare Pharma Tech Co., Ltd. (6) · InnoCare Pharma Inc. (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test ICP-332, phase 3 first.
- Nov 2026ICP-332 in Subjects With Moderate to Severe Atopic DermatitisPhase 3 · Beijing InnoCare Pharma Tech Co., Ltd.
Studies
Open first, then newest update. How each study uses ICP-332 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous UrticariaRecruitingPhase 2/3Beijing InnoCare Pharma Tech Co., Ltd.NCT07378527Written as ICP-332 Tablets
- ICP-332 in Subjects With Moderate to Severe Atopic DermatitisRecruitingPhase 3Beijing InnoCare Pharma Tech Co., Ltd.NCT06775860Written as ICP-332 Tablets
- ICP-332 in Subjects With Non-segmental VitiligoRecruitingPhase 2/3Beijing InnoCare Pharma Tech Co., Ltd.NCT07047612Written as ICP-332 Tablets
- Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic DermatitisRecruitingPhase 2Beijing InnoCare Pharma Tech Co., Ltd.NCT05702268Written as ICP-332
- Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque PsoriasisCompletedPhase 2Beijing InnoCare Pharma Tech Co., Ltd.NCT07251998Written as ICP-332 Tablets
- Phase I Study of ICP-332 in Healthy SubjectsCompletedPhase 1InnoCare Pharma Inc.NCT06530966Written as ICP-332 Tablets
- A Phase I Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Study of ICP-332 in Healthy SubjectsCompletedPhase 1Beijing InnoCare Pharma Tech Co., Ltd.NCT05399030Written as ICP-332